TB-500 is not proven rapid injury repair
No. TB-500 recovery marketing borrows from thymosin beta-4 biology and wound-healing research, but it has not shown replicated human sports-injury outcomes for rapid muscle, tendon, or joint repair.
No. TB-500 recovery marketing borrows from thymosin beta-4 biology and wound-healing research, but it has not shown replicated human sports-injury outcomes for rapid muscle, tendon, or joint repair.
FDA lists thymosin beta-4 fragment, also known as TB-500, among peptide-related substances with immunogenicity, aggregation, peptide-impurity, no identified human-exposure, and unknown-harm concerns. The stronger thymosin beta-4 evidence is mostly mechanism and wound-healing context, not athlete injury trials measuring pain, function, return to training, recurrence, adverse events, product identity, and follow-up. USADA has also listed thymosin beta-4 derivatives such as TB-500 as prohibited growth-factor examples.
What to do instead
Do not treat a TB-500 vial, clinic pitch, or research-chemical label like a rehab plan. Real injuries still need diagnosis, load management, progressive rehab, and clinician guidance when symptoms persist, surgery is involved, infection risk exists, chronic disease or pregnancy changes the risk picture, medications matter, or sport testing applies.
“TB-500 rapidly repairs muscle, tendon, and joint injuries.”
At a glance
- Status: published
- Topic: Supplements
- Author: No Lies Lifting Editorial